Hormonal
Attenuated (slow) heart rate recovery (HRR) after exercise is associated with a significantly increased risk of cardiovascular events and all-cause mortality in the general population.
To assess your long-term cardiovascular risk, measure your heart rate immediately after stopping moderate-to-vigorous exercise and again after 1 or 2 minutes. A smaller drop (attenuated HRR) indicates slower autonomic recovery and is linked to higher mortality risk. This is a simple, non-invasive metric you can track with any basic heart rate monitor to gauge your autonomic health and longevity risk, independent of your weight or blood pressure.
The pooled hazard ratios associated with attenuated HRR versus fast HRR that served as the referent were 1.69 (95% CI 1.05–2.71) for cardiovascular events and 1.68 (95% CI 1.51–1.88) for all-cause mortality.
Why this rating
Meta-analysis of 9 prospective cohort studies with large sample sizes (34k-41k participants) and long follow-up (15-16.5 years), though heterogeneity exists.
Source
Heart Rate Recovery and Risk of Cardiovascular Events and All‐Cause Mortality: A Meta‐Analysis of Prospective Cohort Studies
Shanhu Qiu et al. · Journal of the American Heart Association · 2017
DOI 10.1161/jaha.117.005505
More from this paper
- For every 10 beats per minute (bpm) decrement in heart rate recovery, the risk of cardiovascular events increases by 13% and all-cause mortality by 9%.Good
- Maximal exercise testing protocols yield more significant predictive results for cardiovascular events and all-cause mortality than submaximal protocols when measuring heart rate recovery.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →